News: Exelixis Inc (EXEL.OQ)
EXEL.OQ on NASDAQ Stock Exchange Global Select Market
5.30USD
2:11pm EDT
5.30USD
2:11pm EDT
Price Change (% chg)
$0.12 (+2.32%)
$0.12 (+2.32%)
Prev Close
$5.18
$5.18
Open
$5.20
$5.20
Day's High
$5.38
$5.38
Day's Low
$5.20
$5.20
Volume
443,363
443,363
Avg. Vol
411,971
411,971
52-wk High
$6.04
$6.04
52-wk Low
$4.20
$4.20
Select another date:
Select another date:
- Cramer's Lightning Round - Tesla Remains A Cult Stock (7/16/13)
- 'Mad Money' Lightning Round: I'm Recommending AMD
- Exelixis' Goldman Sachs 34th Annual Global Healthcare Conference - Transcript
- Exelixis And Cabozantinib: ASCO 2013 Highlights
- Tackling Cancer: Your Best Investing Ideas
- New Approvals Spark a Melanoma Drug Battle
Press Releases
- Exelixis Announces Webcast of January 9 Presentation at the J.P. Morgan 31st Annual Healthcare Conference
- Exelixis Announces EMA Acceptance of Marketing Authorization Application For COMETRIQ (cabozantinib)
- FDA Approves COMETRIQ (Cabozantinib) for Treatment of Progressive, Metastatic Medullary Thyroid Cancer
- Exelixis Announces Third Quarter 2012 Financial Results
- Exelixis Announces Webcasts of Upcoming Investor Conference Presentations in November
- Exelixis Announces November 7th Webcast of Third Quarter 2012 Financial Results Conference Call
- Interim Data for Cabozantinib 40 mg Dose Cohort in Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2012 Congress
- Preliminary Phase 1 Data for Cabozantinib in Japanese Patients Presented at ESMO 2012
- Exelixis Announces Data Presentation for GDC-0973 (XL518)
- Exelixis Announces Data Presentations at ESMO 2012 Congress

